These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 24909066)
41. Re: Billis et al.: Does the type of prostatic atrophy influence the association of extent of atrophy in needle biopsies and serum prostate-specific antigen levels? (Urology 2009;74:1111-1115). Papatsoris A; Albanis S; Deliveliotis C Urology; 2010 May; 75(5):1239; author reply 1240. PubMed ID: 20451754 [No Abstract] [Full Text] [Related]
52. It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening. Vickers A; Carlsson S; Laudone V; Lilja H Eur Urol; 2014 Aug; 66(2):188-90. PubMed ID: 24411991 [TBL] [Abstract][Full Text] [Related]
53. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. Mishra VC; Motiwala HG BJU Int; 2004 May; 93(7):1116-7. PubMed ID: 15142181 [No Abstract] [Full Text] [Related]
54. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Stenman UH Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813 [No Abstract] [Full Text] [Related]
55. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer. Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135 [TBL] [Abstract][Full Text] [Related]
56. [Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy]. Miyamoto S; Jimbo H; Totsuka Y; Mashimo T; Umeyama T; Uehara H; Shinozaki T Hinyokika Kiyo; 1995 Oct; 41(10):767-70. PubMed ID: 8533671 [TBL] [Abstract][Full Text] [Related]
57. Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times. Stamey TA Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):967-8; discussion 972. PubMed ID: 7591913 [No Abstract] [Full Text] [Related]
58. Editorial Comment from Dr Satoh to interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer. Satoh T Int J Urol; 2013 Feb; 20(2):149. PubMed ID: 22924812 [No Abstract] [Full Text] [Related]
59. Editorial Comment from Dr Stone to interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer. Stone NN Int J Urol; 2013 Feb; 20(2):148. PubMed ID: 22924786 [No Abstract] [Full Text] [Related]
60. Editorial comment: factor that influence serum prostate-specific antigen levels in terms of maintaining quality within a PSA screening system. Ito K Eur Urol; 2007 Sep; 52(3):714. PubMed ID: 17849514 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]